- Home
- IDYA
as 10-30-2025 4:00pm EST
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Upcoming Earnings Alert:
Get ready for potential market movements as IDEAYA Biosciences Inc. IDYA prepares to release earnings report on 04 Nov 2025.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 2.3B | IPO Year: | 2019 |
| Target Price: | $48.20 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.45 - $33.64 | Next Earning Date: | 11-04-2025 |
| Revenue: | $7,000,000 | Revenue Growth: | -41.48% |
| Revenue Growth (this year): | 90.17% | Revenue Growth (next year): | 219.42% |
Latest IDEAYA Biosciences Inc. News
IDYA Breaking Stock News: Dive into IDYA Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
RBC Raises Price Target on IDEAYA Biosciences to $41 From $38, Keeps Outperform, Speculative Risk
MT Newswires
11 days ago
Ideaya Says Darovasertib With Crizotinib Shows Median Overall Survival of 21.1 Months in Eye Cancer Trial
Insider Monkey
13 days ago
Citizens JMP Remains Bullish on IDEAYA Biosciences (IDYA)
PR Newswire
a month ago
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
2 months ago
Could IDEAYA Biosciences' (IDYA) Expanding Pipeline Redefine Its Long-Term Value Proposition?
MT Newswires
2 months ago
Mizuho Lifts Price Target on IDEAYA Biosciences to $44 From $43, Keeps Outperform Rating
Insider Monkey
2 months ago
Citizens JMP Initiates IDEAYA Biosciences (IDYA) With a Buy Rating
MT Newswires
2 months ago
RBC Capital Adjusts Price Target on IDEAYA Biosciences to $38 From $36, Maintains Outperform, Speculative Risk
Compare IDYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IDYA IDEAYA Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.